Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 11/08/23
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/01/23
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023GlobeNewsWire • 11/01/23
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023GlobeNewsWire • 10/27/23
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023GlobeNewsWire • 10/03/23
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing CollaborationGlobeNewsWire • 10/02/23
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe DiseasePRNewsWire • 10/02/23
Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not MatterSeeking Alpha • 09/29/23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe DiseaseGlobeNewsWire • 09/28/23
Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?Zacks Investment Research • 09/07/23
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023GlobeNewsWire • 09/01/23
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023GlobeNewsWire • 08/29/23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United KingdomGlobeNewsWire • 08/15/23
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 08/08/23
Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)Zacks Investment Research • 08/07/23